Mark Pepys, FMedSci, FRS | oneAMYLOIDOSISvoice

Published: Jul 22, 2019

Tags

Immunology

Mark Pepys is a Director of Wolfson Drug Discovery Unit Centre for Amyloidosis & Acute Phase Proteins and Clinical Research Associate in Department of Medicine at University College London (UCL). He is a physician and immunologist whose work on blood proteins has elucidated mechanisms of disease, identified new targets for treatment and led to improved diagnosis and treatments.

He invented a unique, non-invasive scan for diagnosis and monitoring of patients with amyloidosis, a fatal disease caused by accumulation of abnormal protein fibres in the tissues. His work has greatly improved understanding, management and outcome of the disease, and he founded the world-leading National Amyloidosis Centre, which serves patients from the United Kingdom and many from abroad.

Mark has also designed new therapeutic approaches for amyloidosis and Alzheimer's disease. His treatment for amyloidosis is being developed by GlaxoSmithKline in collaboration with the Wolfson Drug Discovery Unit at UCL, and its clinical trial is providing positive results.

Representative Publications:

Plasminogen Activation Triggers Transthyretin Amyloidogenesis in Vitro

Randomized Phase I Trial HIV-CORE 003: Depletion of Serum Amyloid P Component and Immunogenicity of DNA Vaccination Against HIV-1

Repeat Doses of Antibody to Serum Amyloid P Component Clear Amyloid Deposits in Patients With Systemic Amyloidosis

Pharmacological Removal of Serum Amyloid P Component From Intracerebral Plaques and Cerebrovascular Ab Amyloid Deposits in Vivo

First Name

Mark

Last Name

Pepys

Address

Wolfson Drug Discovery Unit<br>
Centre for Amyloidosis & Acute Phase Proteins<br>
University College London<br>
Rowland Hill Street

Qualification